Pharmacy practice research and development has been a priority for over 10 years, and has been continuously supported under the Third and Fourth Community Pharmacy Agreements.
Pharmacy research and development is one of the priorities identified in the Fifth Agreement and funding of up to $10.6 million has been allocated for the Research and Development (R&D) Program over the life of the Agreement.
The objective of the R&D Program is to contribute to maintaining and improving the health outcomes of Australians through evidence based best practice on issues related to pharmacy and the provision of quality services to patients.
The R&D Program has four outcomes:
The framework of themes developed under the Fourth Agreement will continue to be used to assist in achieving the Program aim by outlining the basis upon which each research proposal will be assessed and prioritised.